Skip to main content
Staff Login
Username
*
Enter your The Contraceptive Pipeline Database username.
Password
*
Enter the password that accompanies your username.
Log in
Forgot password
Toggle navigation
Vicriviroc + MK2048 + Progestin Vaginal Ring
Product Overview
Description:
A vaginal ring whose mechanism of action is CCR5 inhibitor, integrase inhibitor and a progestin for protection against HIV and pregnancy.
Updated date:
May 11, 2015
Vertical Tabs
Product Details
Active Pharmaceutical Ingredient (API):
, ,
Inactive material:
EVA
Partner:
, ,
Status
Status Details:
2-ARV IVR prototype first in human study planned in early 2015. 2-ARV+progestin IVR prototype in preclinical development.
Merck announced that it would discontinue development of its investigational CCR5 antagonist vicriviroc for the treatment of HIV infection in both treatment-naive and treatment-experienced patients, due to unimpressive results in clinical trials.
Programmatic Considerations
Considerations:
Nuvaring technology licensed, manufacturing infrastructure. Nuvaring postmarket acceptability studies completed.
Additional Information
Footnotes:
Vicriviroc is also known as MK4176.
Download Product Report
